Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.11 | N/A | -175.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.11 | N/A | -175.00% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious outlook without offering specific future guidance. They emphasized their commitment to their development pipeline.
Management did not provide specific guidance for future performance.
The company is focused on ongoing development efforts.
The earnings report indicates that Soleno Therapeutics did not meet earnings expectations, which contributed to a slight decline in stock price. Investors may be concerned about the lack of revenue information and forward guidance. The stock's reaction suggests cautious sentiment among investors as the company continues to navigate its development efforts.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SUNCOR ENERGY INC NE
May 3, 2021